Amneal Pharmaceuticals (AMRX) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Amneal Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $9.8M of AMRX stock on the open market.
Get emailed when insiders cluster-buy stocks like AMRX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AMRX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $7.2M | 4 |
| Q2 2026 | — | 0 | $451K | 1 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | $2.2M | 2 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Amneal Pharmaceuticals, Inc. insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $9.8M. 0 of 7 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
AMRX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Jul 30, 2026 | +14.4% | None | -4.1%S&P +2.4% | -4.3% |
| May 7, 2026 | +4.6% | None | -3.1%S&P +0.5% | +4.2% |
| Apr 22, 2026 | +5.4% | None | -2.8%S&P +0.6% | -1.8% |
| Feb 27, 2026 | -1.4% | None | -5.0%S&P -0.4% | -7.7% |
| Jan 13, 2026 | +0.2% | None | +2.1%S&P -0.7% | +11.8% |
| Oct 30, 2025 | +7.3% | None | +3.7%S&P -0.8% | +15.7% |
| Aug 5, 2025 | -0.1% | None | +1.1%S&P +0.3% | +19.5% |
| Jul 21, 2025 | -5.3% | None | -0.1%S&P +0.2% | +19.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 14SEC | John KielyDirector | Sell | 50,000210,252 held (−19%) | $17.64 | $882K | +12.9% | — |
| Aug 13SEC | Jason B. DalyGeneral Counsel | Sell | 210,00035,171 held (−86%) | $17.40 | $3.7M | +14.4% | — |
| Aug 13SEC | Nikita ShahPresident | Sell | 146,403253,390 held (−37%) | $17.51 | $2.6M | +13.7% | — |
| Aug 13SEC | Jason B. DalyGeneral Counsel | Sell | 6,613245,171 held (−3%) | $17.70 | $117K | +12.5% | — |
| May 12SEC | Deborah M. AutorDirector | Sell | 34,81993,660 held (−27%) | $12.94 | $451K | +53.9% | — |
| Nov 19SEC | Ted C NarkDirector | Sell | 50,000291,029 held (−15%) | $11.72 | $586K | +69.9% | — |
| Nov 14SEC | Nikita ShahPresident | Sell | 131,856146,403 held (−47%) | $11.92 | $1.6M | +67.0% | — |
Insiders at Amneal Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Nikita ShahPresident | — | $4.1M | Aug 13, 2026 | — |
| Jason B. DalyGeneral Counsel | — | $3.8M | Aug 13, 2026 | — |
| John KielyDirector | — | $882K | Aug 14, 2026 | — |
| Ted C NarkDirector | — | $586K | Nov 19, 2025 | — |
| Deborah M. AutorDirector | — | $451K | May 12, 2026 | — |
AMRX stock: common questions
Are Amneal Pharmaceuticals, Inc. insiders buying AMRX stock?
In the past 12 months, 0 insiders reported open-market purchases of AMRX worth $0.
Are Amneal Pharmaceuticals, Inc. insiders selling AMRX stock?
5 insiders reported sales worth $9.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AMRX's 52-week range?
Over the past year AMRX has traded between $9.72 and $20.50. It last closed at $19.91 on Oct 9, 2026.